치료용 백신 시장 보고서 : 유형, 질환별, 기술별, 유통 채널별, 지역별(2026-2034년)

The global therapeutic vaccines market size reached USD 37.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 78.5 Billion by 2034, exhibiting a growth rate (CAGR) of 8.32% during 2026-2034. North America dominates the market, driven by rising prevalence of diseases with limited treatment options and technological advancements. Increasing preferences for minimally invasive surgeries (MIS) and the growing partnerships between pharmaceutical companies, research institutions, and academia are some of the major factors propelling the market share.

Therapeutic vaccines, also known as treatment vaccines or immunotherapeutic vaccines, are a type of medical intervention designed to stimulate the immune system of patients to target and combat specific diseases. They have fewer side effects compared to traditional treatments like chemotherapy. They stimulate the immune system without causing extensive damage to healthy cells. They help reduce the likelihood of disease recurrence after initial treatment. They can be combined with other treatments, such as chemotherapy or targeted therapies, to create a synergistic effect. They aid in managing chronic infections like human immunodeficiency viruses (HIV) and hepatitis B by enhancing the immune response to control the viral load and minimize disease progression.

The rising prevalence of diseases with limited treatment options, such as certain types of cancers and rare disorders, is catalyzing the demand for innovative therapeutic approaches like vaccines. Additionally, the increasing aging population aging population, which is highly susceptible to various chronic ailments is driving the need for novel treatment modalities like therapeutic vaccines. Apart from this, governments of various countries are offering supportive policies, grants, and funding for research and development (R&D) in the field of immunotherapy and vaccines. Furthermore, the rising preferences of individuals for non-invasive or minimally invasive treatment options are driving the demand for therapeutic vaccines. Moreover, partnerships between pharmaceutical companies, research institutions, and academia are accelerating the development and commercialization of therapeutic vaccines.

THERAPEUTIC VACCINES MARKET TRENDS:

Rising burden of cancer

The growing global burden of cancer is a key factor fueling the expansion of the market, as conventional treatments like chemotherapy and radiation often come with high toxicity and limited long-term effectiveness. According to the Indian Council of Medical Research, a forecasted 12.8% increase in cancer cases is expected by 2025 relative to 2020. With cancer cases rising due to lifestyle changes, aging population, and environmental factors, there is a growing demand for innovative solutions that provide durable responses with fewer side effects. Therapeutic vaccines, crafted to activate the body's immune system to identify and target tumor cells, are emerging as a promising option. Their ability to complement existing therapies and potentially prevent relapse makes them highly attractive. As cancer incidence continues to rise worldwide, healthcare providers and research organizations are prioritizing vaccine-based therapies, thereby accelerating investments and adoption across the market.

Growing focus on immunotherapy

Rising focus on immunotherapy as a frontline approach to treating chronic and life-threatening diseases is driving momentum in the market. Unlike conventional treatments that directly target diseased cells, immunotherapy leverages the patient's immune system to identify and target harmful agents, offering longer-lasting effects and lesser toxicity. In September 2025, a cutting-edge cancer immunotherapy from BioNTech and partner Bristol Myers Squibb (BMY.N) showed promising tumor reduction in a mid-stage trial for small cell lung cancer that was beginning to metastasize. A Phase II trial indicated that 76.3% of the 38 participants receiving the drug BNT327, or pumitamig, who met criteria for an interim analysis experienced a decrease in their tumors. Therapeutic vaccines act as immune stimulants to target cancer cells, viruses, or other disease-causing agents. As immunotherapy is gaining credibility through successful outcomes in oncology and infectious disease management, the demand for vaccine-based immunotherapies is rising.

Increasing personalized medicine demand

Rising demand for personalized medicine is positively influencing the market, as patients and clinicians are seeking targeted treatments tailored to individual genetic and molecular profiles. As per the IMARC Group, the global precision medicine market size reached USD 82.1 Billion in 2024. Unlike traditional one-size-fits-all approaches, therapeutic vaccines can be developed to match specific tumor antigens or immune system variations, enhancing treatment outcomes and minimizing adverse effects. Advancements in genomics and biomarker discovery are enabling researchers to design vaccines that align with patients' unique biological characteristics, paving the way for more precise and effective therapies. This shift towards personalization is not only improving patient satisfaction and survival rates but also attracting higher investments in vaccine research and development (R&D) activities.

KEY GROWTH DRIVERS OF THERAPEUTIC VACCINES MARKET:

Advancements in technology

Advancements in deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) vaccine technology are offering a favorable market outlook by enabling faster development, higher efficacy, and broader application potential. These platforms allow precise encoding of antigens that stimulate strong and targeted immune responses against specific diseases, including cancer and chronic infections. Unlike traditional vaccines, DNA and mRNA technologies can be quickly designed, manufactured, and scaled, reducing both cost and development timelines. Their flexibility also supports customization for personalized therapies, aligning well with the shift towards precision medicine. As innovation continues, DNA and mRNA vaccines are expected to unlock new treatment possibilities, driving robust growth and adoption in the market.

Expanding collaborations between biotech firms and academia

Rising partnerships between biotech firms and academic institutions are positively influencing the market, bridging cutting-edge scientific research with commercial development expertise. Academic institutions often drive early-stage discoveries, such as identifying novel antigens or immune mechanisms, while biotech companies bring the resources and infrastructure needed for clinical trials, regulatory approval, and commercialization. These collaborations aid in accelerating innovations, reducing time-to-market, and enhancing the chances of success in a highly complex and high-risk field like vaccine development. Furthermore, alliances promote knowledge sharing, access to advanced technologies, and training of skilled professionals. By pooling intellectual and financial resources, biotech-academia partnerships are creating a strong pipeline of therapeutic vaccine candidates, significantly advancing the market growth trajectory.

Rising government funding for vaccine development

Increasing government funding for vaccine development is a major driver of the market growth, as public sector support provides the financial backbone needed to advance innovative research and clinical trials. Government agencies across developed and emerging economies are allocating significant resources to strengthen healthcare infrastructure, promote biotechnology innovation, and accelerate the availability of advanced therapies for chronic and infectious diseases. Such funding reduces the risk for private companies, encouraging collaboration and faster translation of discoveries into market-ready products. Moreover, government-backed initiatives help create regulatory incentives, improve access to cutting-edge platforms, and foster international partnerships. This proactive financial and policy support ensures sustained innovations and widespread adoption, ultimately positioning therapeutic vaccines as a vital component of modern healthcare strategies.

THERAPEUTIC VACCINES INDUSTRY SEGMENTATION:

Breakup by Type:

• Antigen Vaccines
• Dendritic Cell Vaccine
• DNA Vaccine
• Tumor Cell Vaccines

Tumor cell vaccines hold the largest market share

Breakup by Disease Type:

• Autoimmune Disease Vaccines
• Addiction Vaccine
• Neurological Disease Vaccine
• Infectious Disease Vaccine
• Others

Autoimmune disease vaccines represent the largest market segment

Breakup by Technology:

• Autologous Vaccines
• Allogeneic Vaccine

Autologous vaccines account for the majority of the market share

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hospital pharmacies operate within healthcare facilities, which ensures direct access to patients undergoing treatments. They facilitate immediate availability, expert guidance, and seamless integration with medical care and aid in dispensing and administering therapeutic vaccines, especially for critical conditions requiring close medical supervision.

Retail pharmacies are widespread and easily accessible to the general population. They offer convenience and a wide range of healthcare products, including therapeutic vaccines. Additionally, they cater to diverse patient needs, making therapeutic vaccines more accessible to the masses.

Online pharmacies offer a convenient platform to purchase therapeutic vaccines remotely. They provide a wide selection, price comparisons, and home delivery, which are particularly advantageous for patients with mobility limitations or those seeking privacy.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest therapeutic vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region has a well-developed healthcare infrastructure, comprising modern hospitals, research institutions, and pharmaceutical companies, which accelerates research, development, and commercialization of therapeutic vaccines. Additionally, North America is a global hub for medical research and innovation, housing renowned universities, research centers, and biotechnology firms. Apart from this, regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain rigorous standards for drug and vaccine approvals. Moreover, North America has a well-established clinical trial ecosystem, which facilitates the efficient testing and validation of therapeutic vaccines. The availability of diverse patient populations and expert medical professionals expedites the trial process.

COMPETITIVE LANDSCAPE:

Companies are investing in research to identify novel antigens and develop innovative vaccine platforms, which include exploring cutting-edge technologies like mRNA-based vaccines, viral vectors, and personalized vaccine approaches. Additionally, many vaccine developers are conducting rigorous clinical trials to evaluate the safety and efficacy of their products. Furthermore, they are working closely with regulatory agencies to obtain approvals for their therapeutic vaccines. This involves compiling comprehensive data from clinical trials to demonstrate safety, efficacy, and manufacturing quality. Moreover, many leading companies are investing in infrastructure and technologies to ensure consistent and efficient vaccine production.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Agenus Inc.
• Bavarian Nordic
• CEL-SCI Corporation
• Dendreon Pharmaceuticals LLC
• Emergent BioSolutions
• GeoVax
• GSK plc
• Merck & Co., Inc.
• Novavax
• Nykode Therapeutics ASA
• Pfizer Inc.
• Phio Pharmaceuticals
• Sanofi S.A

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global therapeutic vaccines market in 2025?

2. What is the expected growth rate of the global therapeutic vaccines market during 2026-2034?

3. What are the key factors driving the global therapeutic vaccines market?

4. What has been the impact of COVID-19 on the global therapeutic vaccines market?

5. What is the breakup of the global therapeutic vaccines market based on the type?

6. What is the breakup of the global therapeutic vaccines market based on the disease type?

7. What is the breakup of the global therapeutic vaccines market based on the technology?

8. What are the key regions in the global therapeutic vaccines market?

9. Who are the key players/companies in the global therapeutic vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Therapeutic Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Antigen Vaccines
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Dendritic Cell Vaccine
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 DNA Vaccine
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Tumor Cell Vaccines
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Disease Type

• 7.1 Autoimmune Disease Vaccines
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Addiction Vaccine
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Neurological Disease Vaccine
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Infectious Disease Vaccine
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Technology

• 8.1 Autologous Vaccines
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Allogeneic Vaccine
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Retail Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Online Pharmacies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agenus Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Bavarian Nordic
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
  • 15.3.3 CEL-SCI Corporation
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Dendreon Pharmaceuticals LLC.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Emergent BioSolutions
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 GeoVax
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 GSK plc
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Merck & Co., Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Novavax
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Nykode Therapeutics ASA
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Pfizer Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Phio Pharmaceuticals
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Sanofi S.A
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials
    • 15.3.13.4 SWOT Analysis